Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

Times are changing, and unpredictability has become the new normal when it comes to tariffs and world trade. Nobody outside ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

A North Carolina woman has filed a lawsuit in New Jersey federal court, claiming that her use of the diabetes medication ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

A daily pill from Eli Lilly lowered blood sugar levels and induced weight loss in people with Type 2 diabetes, the company ...

Eli Lilly has followed Novo Nordisk in announcing a big investment ... with investment projects ongoing in North Carolina and Indiana in the US. The new facility in Germany is preparing for ...

Start your morning by catching up on Daniel Murray’s article on Darragh O’Brien’s pause on next phase of smoky coal ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...